Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1988;16(1):8-12.
doi: 10.1007/BF01646921.

A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora

C Edlund  1 , C E Nord
Affiliations
Review

A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora

C Edlund et al. Infection. 1988.

Abstract

During the last few years the impact of the newer 4-quinolones, ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin, on the human microflora has been studied by several investigators. This review article summarizes the published data concerning these studies. The results show that the oropharyngeal flora is affected only slightly or not at all by the 4-quinolones. All the newer 4-quinolones have a similar effect on the normal intestinal flora. The gram-negative aerobic flora is strongly suppressed during administration of 4-quinolones, while the gram-positive flora is only slightly affected. The anaerobic microflora is hardly affected at all. The emergence of resistant bacterial strains is uncommon, although one study shows increased MIC-values for anaerobes during ciprofloxacin administration. Replacement by yeasts or other inherently resistant microorganisms does not often seem to be a problem. High concentrations of the 4-quinolones are reached in faeces, values between 100-2,200 mg/kg being reported. Since the 4-quinolones do not cause marked ecological disturbances in the intestinal microflora, they may be suitable for selective decontamination in immunocompromised patients, for prophylaxis of urinary tract infections and for treatment of bacterial intestinal infections.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Infection. 1983;11 Suppl 2:S90-2 - PubMed
    1. Am J Med. 1984 May 15;76(5A):99-106 - PubMed
    1. J Infect Dis. 1985 Jul;152(1):104-7 - PubMed
    1. Prog Clin Biol Res. 1985;181:259-62 - PubMed
    1. Antimicrob Agents Chemother. 1986 Jun;29(6):1047-52 - PubMed